A Calgary-based company has earned emergency clearance from the U.S. Food and Drug Administration to market a liquid ivermectin product for horses, aimed at short-term prevention of screwworm in the United States. The approval comes as authorities face growing concerns over the cattle parasite and its potential spread.
According to the report, the FDA’s emergency authorization covers the Solvet product, enabling its sale and use specifically for screwworm prevention in the near term. The development marks a notable escalation in the tools available to counter the screwworm threat, which has heightened risk discussions in the U.S. cattle industry.
The announcement highlights Solvet, the Calgary company behind the ivermectin formulation, as taking a proactive step to support U.S. efforts against the disease. The regulatory decision enables immediate accessibility of the product for horses, with the hope of mitigating outbreaks linked to screwworm nears.
The news arrives amid broader efforts to control screwworm across North America, signaling a practical deployment of veterinary pharmaceuticals to address the livestock parasite. While the approval focuses on horses, the underlying objective is to reduce the risk of screwworm spread, safeguarding cattle and related agricultural sectors.
No additional details on dosage, distribution, or the scope of the emergency authorization are provided in the report. The record emphasizes the FDA’s decision as an enabling measure for Solvet’s product in the ongoing battle against screwworm in the United States.
